Severe inflammatory myopathy in a pulmonary carcinoma patient treated with Pembrolizumab: An alert for myologists
Articolo
Data di Pubblicazione:
2020
Citazione:
Severe inflammatory myopathy in a pulmonary carcinoma patient treated with Pembrolizumab: An alert for myologists / L. Peverelli, A. De Rosa, E. Domina, P. Ciscato, G. Sita, D. Velardo, G.P. Comi. - In: JOURNAL OF NEUROMUSCULAR DISEASES. - ISSN 2214-3599. - 7:4(2020), pp. 511-514.
Abstract:
Immune-related adverse events (irAE) during the administration of immune-checkpoint inhibitors (ICIs) become more evident due to the increased use of these therapies. To remind the importance of early recognition of this phenomenon, we report a paradigmatic case characterized by severe systemic inflammatory myopathy and severe cardiac involvement that abruptly precipitated in an untoward ending after one single dose of Pembrolizumab.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
immune-checkpoint inhibitors; immune-correlated adverse events; inflammatory myopathy; Pembrolizumab; pulmonary carcinoma;
Elenco autori:
L. Peverelli, A. De Rosa, E. Domina, P. Ciscato, G. Sita, D. Velardo, G.P. Comi
Link alla scheda completa: